Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING
RANDOX LABORATORIES

EKF Diagnostics Acquires Selah Genomics and DiaSpect Medical

By Labmedica International staff writers
Posted on 30 Apr 2014
EKF Diagnostics (Cardiff, Wales, UK), a global in vitro diagnostics business, has acquired Selah Genomics, Inc. and DiaSpect Medical AB, enhancing its hemoglobin analysis and personalized medicine capabilities. Sweden based DiaSpect manufactures desktop hemoglobin analyzers, while Selah, of South Carolina (USA), is a service provider that supplies molecular diagnostics tests for the development of personalized medicine.

The integration of DiaSpect’s product line into the existing portfolio of EKF hemaglobin analyzers will enable the provision of an analyzer to meet any need. The patented DiaSpect Hb-system provides instant results from one drop of whole blood. It is suitable for use in dry or humid conditions, and the broad-spectrum photometer together with the reagent-free cuvette is reliable and cost-effective. This desktop device will join the point of care (POC) Hemo Control (Hemo Point H2 in the USA) and the hand-held, portable STAT-Site hemoglobin analyzer.

The acquisition of Selah Genomics enables EKF to extend its molecular diagnostics offering to support healthcare providers and the pharmaceutical industry with advanced molecular and genomic diagnostic services. The easy-to-use service provides doctors with a sample kit, and once they have obtained a swab from the patient, it is simply sealed and posted back for analysis. Resulting data can be used to develop personalized treatment plans.

Combined with the recent acquisition of Separation Technology, Inc. this purchase has strengthened EKF’s product and services offering, positioning EKF at the forefront of the POC hematology testing provision. EKF now offers a comprehensive and cost-effective product range, as well as being able to participate in personalized medicine; an area which is quickly becoming important in the in vitro diagnostic (IVD) industry.

Julian Baines, CEO of EKF, commented, “These acquisitions provide us with a huge opportunity to establish ourselves as a leading global player in point of care hemoglobin testing and to consider our position in molecular diagnostics and personalized medicine, an area which we consider to be one of the most exciting in diagnostics.”

EKF Diagnostics Holdings plc which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc, DiaSpect, and Selah Genomics brands specializes in the development, production, and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division focuses on molecular and companion diagnostics.

Related Links:

EKF Diagnostics



PURITAN MEDICAL
EUROIMMUN AG
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Pathology

view channel

New Approach Identifies Multiple Melanoma Drug Resistance Biomarkers

A recent paper described the use of liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM) for assessing melanoma biomarkers in the blood in order to determine the effectiveness of chemotherapy. Modern chemotherapeutic techniques based on treatment with multiple anticancer drugs require the identification... Read more

Lab Technology

view channel
Image: Visualization from a numerical simulation of a cell flowing past the obstacle through the microfluidic device (Image courtesy of KTH – The Royal Institute of Technology).

Microfluidic Device Could Improve Biomarker Analyses

A new microfluidic device could offer a more reliable alternative for detecting biomarkers in patients facing such illnesses as cancer or malaria. The physical attributes of cells are important biomarkers... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.